uniQure N.V.
QURE
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.63B
Close$
$-8.51
136.3% downside
Current Fair Value
136.3% downsideOvervalued by 136.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.63 Billion |
|---|---|
| Enterprise Value | $1.28 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.46 |
| Beta | 0.94 |
| Outstanding Shares | 66,243,879 |
Return
| Return on Equity | -77.83% |
|---|---|
| Return on Assets | -25.60% |
| Return on Invested Capital | -29.63% |
Valuation & Multiples
| P/E Ratio | -5.81 |
|---|---|
| PEG | -5.05 |
| Price to Sales | - |
| Price to Book Ratio | 5.87 |
| Enterprise Value to Revenue | 68.4 |
| Enterprise Value to EBIT | -4.78 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.19 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 4, 2026
EPS Estimate
$-0.82
Average shareholder expectationRevenue Estimate
$5.45 M
Average shareholder expectationNext Earnings Call
Expected Date
November 9, 2026
EPS Estimate
$-0.84
Average shareholder expectationRevenue Estimate
$6.21 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2160▲ 6.78% |
|---|---|
| Total Calls | 9,749,931▼ 31.71% |
| Total Puts | 2,105,788▼ 0.45% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 99.33%▼ 4.60% |
|---|---|
| Total Invested | $3.04B▲ 212.37% |
| Investors Holding | 302▲ 42.00% |
ESG Score
No data
About uniQure N.V.
uniQure is delivering on the promise of gene therapy - single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to tr...